MedTrace Logo

45th Multicenter Airway Research Collaboration

NCT07166939 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1860

Last updated 2026-04-17

No results posted yet for this study

Summary

The study is a randomized controlled trial on the effect of emergency department initiation of Airsupra on acute asthma "recurrence" at 3 months and other related outcomes (acute asthma relapse, asthma control).

Conditions

  • Asthma Acute
  • Asthma Exacerbation
  • Asthma
  • Asthma Control Level

Interventions

DRUG

Airsupra

1 dose (2 inhalations) PRN, with maximum of 6 doses (12 inhalations) in a 24-hour period

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
54 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-07
Primary Completion
2027-06-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07166939 on ClinicalTrials.gov